IL135586A0 - α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Google Patents

α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Info

Publication number
IL135586A0
IL135586A0 IL13558698A IL13558698A IL135586A0 IL 135586 A0 IL135586 A0 IL 135586A0 IL 13558698 A IL13558698 A IL 13558698A IL 13558698 A IL13558698 A IL 13558698A IL 135586 A0 IL135586 A0 IL 135586A0
Authority
IL
Israel
Prior art keywords
unsubstituted
substituted
hydroxy
amino
pharmaceutical compositions
Prior art date
Application number
IL13558698A
Other languages
English (en)
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of IL135586A0 publication Critical patent/IL135586A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL13558698A 1997-11-21 1998-11-18 α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME IL135586A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7265597P 1997-11-21 1997-11-21
PCT/IB1998/002154 WO1999026909A2 (fr) 1997-11-21 1998-11-18 DERIVES α-HYDROXY, AMINO ET HALO D'ACIDES HYDROXAMIQUES β-SULFONYLE UTILISES COMME INHIBITEURS DE METALLOPROTEINASES MATRICIELLES

Publications (1)

Publication Number Publication Date
IL135586A0 true IL135586A0 (en) 2001-05-20

Family

ID=22108985

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13558698A IL135586A0 (en) 1997-11-21 1998-11-18 α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME

Country Status (24)

Country Link
US (2) US20030166687A1 (fr)
EP (1) EP1037868B1 (fr)
JP (1) JP2001524462A (fr)
KR (1) KR20010032319A (fr)
CN (1) CN1168709C (fr)
AT (1) ATE232192T1 (fr)
AU (1) AU763113B2 (fr)
BG (1) BG104346A (fr)
BR (1) BR9814699A (fr)
CA (1) CA2310401A1 (fr)
DE (1) DE69811273T2 (fr)
DK (1) DK1037868T3 (fr)
EA (1) EA003585B1 (fr)
ES (1) ES2192349T3 (fr)
HU (1) HUP0100812A3 (fr)
IL (1) IL135586A0 (fr)
IS (1) IS1954B (fr)
NO (1) NO20002505L (fr)
NZ (1) NZ503997A (fr)
PL (1) PL341153A1 (fr)
PT (1) PT1037868E (fr)
TR (1) TR200001391T2 (fr)
UA (1) UA66818C2 (fr)
WO (1) WO1999026909A2 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030166687A1 (en) * 1997-11-21 2003-09-04 Warpehoski Martha A. Alpha-hydroxy,-amino and -fluoro derivatives of beta-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
GB9927453D0 (en) * 1999-11-19 2000-01-19 Pharmacia & Upjohn Spa Crystalline and optically active form of a-hydroxy derivatives of ›-sulfonyl acid
EP2292593A3 (fr) 2000-09-29 2011-05-25 TopoTarget UK Limited Composés d'acide carbamique comportant une liaison de sulfamide en tant qu'inhibiteurs HDAC
ATE430567T1 (de) * 2000-09-29 2009-05-15 Topotarget Uk Ltd Carbaminsäurederivate enthaltend eine amidgruppe zur behandlung von malaria
WO2004060346A2 (fr) 2002-12-30 2004-07-22 Angiotech International Ag Liberation de medicaments a partir d'une composition polymere a gelification rapide
DE10320453A1 (de) * 2003-05-08 2004-11-25 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Bioisostere von Actinonin
EP1966132A2 (fr) * 2005-12-15 2008-09-10 Boehringer Ingelheim International Gmbh Composes qui modulent le recepteur cb2
US7935715B2 (en) * 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CN101516839A (zh) * 2006-09-25 2009-08-26 贝林格尔.英格海姆国际有限公司 调节cb2受体的化合物
US7539361B2 (en) * 2006-10-05 2009-05-26 Harris Corporation Fiber optic device for measuring a parameter of interest
DE102006049618A1 (de) * 2006-10-20 2008-05-08 Tschesche, Harald, Prof. Dr. Triazine und Ihre Verwendung als Metalloproteinase-Inhibitoren
JP5492092B2 (ja) * 2007-11-07 2014-05-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節する化合物
CA2730037A1 (fr) * 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Composes sulfones qui modulent le recepteur cb2
AP2011005674A0 (en) * 2008-09-25 2011-04-30 Boehringer Ingelheim Int Sulfonyl compounds which selectively modulate the CB2 receptor.
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
WO2010147791A1 (fr) 2009-06-16 2010-12-23 Boehringer Ingelheim International Gmbh Dérivés d'azétidine 2-carboxamide qui modulent le récepteur cb2
JP2013505295A (ja) * 2009-09-22 2013-02-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を選択的に調節する化合物
US9315454B2 (en) 2010-01-15 2016-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
EP2542539B1 (fr) 2010-03-05 2014-02-26 Boehringer Ingelheim International GmbH Composés tétrazoles qui modulent sélectivement le récepteur cb2
US8846936B2 (en) 2010-07-22 2014-09-30 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the CB2 receptor
EP2803668A1 (fr) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Nouveau (cyano-dimethyl-methyl)-isoxazoles et - [1,3,4] thiadiazoles
PT3013796T (pt) * 2013-06-27 2020-03-26 Lg Chemical Ltd Derivados biarílicos como agonistas de gpr120
EP3717481B1 (fr) 2017-11-27 2023-03-01 Council of Scientific & Industrial Research Dérivés d'indole (sulfomyl) n-hydroxy benzamide en tant qu'inhibiteurs sélectifs de hdac

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
DE69728375T2 (de) 1996-01-02 2005-02-10 Aventis Pharmaceuticals Inc. Substituierte (aryl, heteroaryl, arylmethyl oder heteroarylmethyl) hydroxamisaeureverbindungen
EP0994104A4 (fr) 1996-06-27 2001-09-12 Ono Pharmaceutical Co Derives d'aryle (sulfure, oxyde sulfonique et sulfone) et medicaments les contenant en tant que principe actif
AU730464B2 (en) 1996-08-07 2001-03-08 Darwin Discovery Limited Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
KR20000048639A (ko) * 1996-09-27 2000-07-25 로렌스 티. 마이젠헬더 매트릭스 메탈로프로테이나제 억제제인 베타-술포닐 히드록삼산
EP0960096B1 (fr) * 1997-01-22 2005-04-06 Aventis Pharmaceuticals Inc. Acides beta-thiocarboxyliques substitues
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
WO1998039326A1 (fr) * 1997-03-04 1998-09-11 Monsanto Company Composes aromatiques d'acide sulfonyle alpha-hydroxy hydroxamique
DK0973392T3 (da) * 1997-03-04 2004-03-29 Monsanto Co Divalente sulfonyl-aryl eller heteroarylhydroxamsyreforbindelser
US20030166687A1 (en) * 1997-11-21 2003-09-04 Warpehoski Martha A. Alpha-hydroxy,-amino and -fluoro derivatives of beta-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors

Also Published As

Publication number Publication date
ES2192349T3 (es) 2003-10-01
ATE232192T1 (de) 2003-02-15
WO1999026909A2 (fr) 1999-06-03
NO20002505L (no) 2000-06-30
JP2001524462A (ja) 2001-12-04
PT1037868E (pt) 2003-06-30
EP1037868B1 (fr) 2003-02-05
BG104346A (en) 2001-01-31
TR200001391T2 (tr) 2000-11-21
US6437177B1 (en) 2002-08-20
PL341153A1 (en) 2001-03-26
EP1037868A2 (fr) 2000-09-27
AU2540599A (en) 1999-06-15
IS1954B (is) 2004-10-13
US20030166687A1 (en) 2003-09-04
BR9814699A (pt) 2000-10-03
WO1999026909A3 (fr) 1999-08-26
CN1278247A (zh) 2000-12-27
HUP0100812A2 (hu) 2001-08-28
EA200000551A1 (ru) 2000-10-30
NZ503997A (en) 2001-09-28
IS5475A (is) 2000-04-28
KR20010032319A (ko) 2001-04-16
CA2310401A1 (fr) 1999-06-03
DE69811273D1 (de) 2003-03-13
HUP0100812A3 (en) 2002-11-28
NO20002505D0 (no) 2000-05-15
DE69811273T2 (de) 2003-12-11
EA003585B1 (ru) 2003-06-26
DK1037868T3 (da) 2003-05-12
UA66818C2 (uk) 2004-06-15
AU763113B2 (en) 2003-07-10
CN1168709C (zh) 2004-09-29

Similar Documents

Publication Publication Date Title
IL135586A0 (en) α-HYDROXY, -AMINO, AND HALO DERIVATIVES OF β-SULFONYL HYDROXAMIC ACIDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
MX9801578A (es) Feniloxazolidinonas que tienen un enlace c-c para anillos heterociclicos de 4-8 miembros.
EA199900332A1 (ru) β-СУЛЬФОНИЛ ГИДРОКСАМОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ МАТРИЧНЫХ МЕТАЛЛОПРОТЕИНАЗ
GEP20022709B (en) Pharmaceutical Compositions Having Appetite Suppressant Activity
GEP20084496B (en) Benzothiophene compound, intermediate, composition, and method
YU29601A (sh) Novi estri izvedeni iz supstituisanih fenil-cikloheksil jedinjenja
AU686520B2 (en) Macrocyclic immunomodulators
AU7077894A (en) Immunosuppressant and antiallergic compounds, e.g. n-(3-oxohexanoyl) homoserine lactone
GR3020513T3 (en) Octapeptide analogs of somatostatin having threonine at the sixth position
AR012603A1 (es) Inhibidor de proteasa, composicion farmaceutica que lo comprende y el uso del mismo para la fabricacion de un medicamento; e intermediarios de sintesis
AU3043192A (en) Thiazolidine compounds, their preparation and their therapeutic uses
IL136100A0 (en) Biphenylamidine derivatives, prodrugs thereof and pharmaceutical compositions containing the same
AU1466295A (en) Amino acid derivatives and their use as phospholipase a2 inhibitors
ZA945435B (en) 1-aryloxy-3-alkylamino-2-propanol nitrate esters the use thereof and corresponding pharmaceutical composition
FI933719A (fi) 4-((2-bensotiazolyl)metylamino)-a-((3,4-difluorfenoxi)metyl)-1-piperidinetanol
IL108970A0 (en) Substituted (arylalkylaminobenzyl) aminopropionamide derivatives, their preparation and pharmaceutical compositions containing them
NZ505543A (en) N-[cis-2-(6-halo, 2-hydroxy, 3-propionylphenyl)-cyclopropyl]-N'-pyrid-2-yl-urea derivatives and salts, prodrugs, pharmaceuticals thereof; useful for the treatment or prophylaxis of HIV
ATE293616T1 (de) 2-fluoro-(oxido-thiopyran-4-yl)benzol derivate
BR9305752A (pt) Composto composiçao farmaceutica e processo para a preparaçao de um composto de derivados alquila da trazodona
WO2002017954A1 (fr) Medicaments contre la maladie de parkinson
GB2333293B (en) Process for the preparation of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide used as anti cancer compounds
ES2067417A1 (es) Procedimiento para preparar nuevos derivados en n de (feniletil-beta-ol)-amina.
HUT65376A (en) Process for preparing n,n',n-trisubstituted 5-(diamino-methylene)-1,3-dioxane-4,6-diones and pharmaceutical compositions containing them as active ingredient
TH25498A (th) สารประกอบเบนโซไธโอฟีน,สารขั้นกลาง,องค์ประกอบและวิธี
MY115721A (en) Benzothiophene compounds, intermediates, compositionsm, and methods